Urogen Pharma (NASDAQ:URGN) Insider Mark Schoenberg Sells 871 Shares of Stock

Urogen Pharma (NASDAQ:URGN) insider Mark Schoenberg sold 871 shares of the company’s stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $42.92, for a total transaction of $37,383.32. Following the completion of the sale, the insider directly owned 59,882 shares in the company, valued at $2,570,135.44. This represents a 1.43% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Mark Schoenberg also recently made the following trade(s):

• On Thursday, August 20th, Mark Schoenberg sold 60,677 shares of Urogen Pharma stock. The stock was sold at an average price of $47.05, for a total transaction of $2,854,852.85.
• On Thursday, July 9th, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The shares were sold at an average price of $40.00, for a total transaction of $400,000.00.
• On Monday, June 22nd, Mark Schoenberg sold 10,000 shares of Urogen Pharma stock. The stock was sold at an average price of $35.01, for a total transaction of $350,100.00.

Urogen Pharma Trading Up 1.8%

URGN traded up $0.79 during midday trading on Wednesday, reaching $44.60. The company’s stock had a trading volume of 648,104 shares, compared to its average volume of 807,203. Urogen Pharma has a 1 year low of $15.86 and a 1 year high of $50.81. The stock’s 50-day moving average is $43.02 and its 200-day moving average is $31.15. The firm has a market capitalization of $2.18 billion, a price-to-earnings ratio of -22.61 and a beta of 1.57.

Urogen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, August 5th. The company reported ($0.28) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.26) by ($0.02). The firm had revenue of $72.46 million for the quarter, compared to analysts’ expectations of $63.55 million. As a group, equities research analysts forecast that Urogen Pharma will post -0.2 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts have recently commented on URGN shares. TD Cowen increased their target price on Urogen Pharma from $50.00 to $60.00 and gave the stock a “buy” rating in a research note on Wednesday, August 5th. UBS Group reiterated a “buy” rating on shares of Urogen Pharma in a research note on Thursday, July 9th. HC Wainwright increased their price objective on shares of Urogen Pharma from $45.00 to $75.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. The Goldman Sachs Group restated a “neutral” rating and set a $44.00 price objective on shares of Urogen Pharma in a research note on Wednesday, July 15th. Finally, Oppenheimer upped their target price on shares of Urogen Pharma from $40.00 to $50.00 and gave the stock an “outperform” rating in a research note on Thursday, July 16th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $50.38.

Institutional Investors Weigh In On Urogen Pharma

Several large investors have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Urogen Pharma by 7.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 23,320 shares of the company’s stock worth $258,000 after buying an additional 1,653 shares during the last quarter. Persistent Asset Partners Ltd purchased a new stake in shares of Urogen Pharma during the 2nd quarter valued at about $66,000. Main Street Financial Solutions LLC grew its stake in shares of Urogen Pharma by 8.2% in the second quarter. Main Street Financial Solutions LLC now owns 25,968 shares of the company’s stock worth $356,000 after acquiring an additional 1,968 shares during the period. Barclays PLC raised its holdings in shares of Urogen Pharma by 3.8% during the fourth quarter. Barclays PLC now owns 57,744 shares of the company’s stock valued at $1,352,000 after purchasing an additional 2,125 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new position in shares of Urogen Pharma during the second quarter valued at approximately $78,000. 91.29% of the stock is currently owned by institutional investors.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.